NervGen Pharma (NGEN)
Develops NVG-291 for spinal-cord injury.
$2.02
vs last close−0.05 (−2.42%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 14.59% | 11.99M shares | |
|---|---|---|---|
| 65 holders · as of Jun 30, 2026 | |||
| Other | 85.41% | 70.20M shares | |
| remainder | |||
82.19M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
65 holders · 11.99M shares · 22 new positions · 42 increased · 7 reduced · 3 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Empery Asset Management, LP | 4.00M | 4.87% | +4.00Mnew | Aug 11, 2026 |
| Rock Springs Capital Management LP | 1.21M | 1.47% | +1.21Mnew | Aug 14, 2026 |
| Dafna Capital Management LLC | 1.05M | 1.28% | +1.05Mnew | Aug 14, 2026 |
| Ghisallo Capital Management LLC | 1.00M | 1.22% | +1.00Mnew | Aug 14, 2026 |
| Armistice Capital, LLC | 678.0K | 0.82% | +678.0Knew | Aug 14, 2026 |
| LMR Partners LLP | 600.0K | 0.73% | +600.0Knew | Aug 14, 2026 |
| Marshall Wace, LLP | 436.0K | 0.53% | +235.6K | Aug 13, 2026 |
| UBS Group AG | 379.7K | 0.46% | +318.2K | Aug 13, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.